Paratek Pharmaceuticals develops and commercialises antibiotic products. Paratek’s NUZYRA® is an FDA-approved tetracycline-class antibiotic designed to address a significant unmet need for adult patients with CABP and ABSSSI caused by susceptible bacteria. Gurnet Point Capital and Novo Holdings acquired Paratek for $462 million in 2023.